Unleash AI’s potential

Measuring the return from pharmaceutical innovation – 14th edition
Seize the digital momentum

Our report series Measuring the return from pharmaceutical innovation has provided insights into the productivity of biopharma R&D since 2010. We have expanded our analysis over time, and our dataset now covers the top 20 companies by 2020 R&D spend. The past 14 years have demonstrated that transformational change in R&D productivity is required to reverse the declining trends in returns across the biopharma industry and the ongoing challenge of continuing to deliver innovation to patients.

Our latest analysis shows that this conclusion is more relevant than ever, given that companies are facing a more challenging regulatory landscape, growing cost pressures, declining peak sales, and difficulties in replenishing their pipelines, with the result that projected R&D returns continue to remain well below the cost of capital.

Download the full report


Key findings

Projected returns from innovation have improved this year

Our analysis over the past 14 years has shown a steady decline in productivity between 2010 and 2019, a short-lived improvement due to the impact of the COVID-19 assets in 2020 and 2021, followed by a dip in 2022. In the 2023 cycle, we are beginning to see signs of some improvement. This year’s modeling, based on a dataset that includes an expanded scope of assets and line extensions, calculates that the internal rate of return (IRR) has risen to 4.1%, from 1.2% last year, which was the lowest point for the cohort since our analysis began.

Read more

IRR depends on both efficiency and value creation

Total reported R&D spend by our cohort has increased from $139.2 billion in 2022 to $145.5 billion in 2023, an increase of 4.5%. The average R&D cost to progress an asset from discovery to launch has remained flat for 2022–2023 at $2.3 billion per asset, reflecting an expanded range of assets and line extensions in the analysis this year.

The cohort’s average forecast peak sales per pipeline asset fell from $389 million in 2022 to $362 million in 2023. This continues the decline from the 2021 peak ($500 million) that was driven by high-value COVID-19 assets. Reflecting the successful approval of high-value assets that we have observed year over year, the total revenue for our cohort with reported top 20 pharma R&D sales increases by 9.6% in 2023.

Opportunities to tackle the drivers of IRR and improve productivity

This year, regulatory changes, the impending and unprecedented scale of the loss of exclusivity of high-value assets for many companies in our cohort, inflationary pressures, the rapid pace of scientific and technological advances, and rising protocol design complexity are all placing significant pressures on the current R&D operating model, but they are also creating new opportunities to improve R&D productivity.

AI-enabled digital transformation is fast becoming a strategic imperative for leaders in life sciences. The biopharma industry is on the brink of large-scale disruption driven by interoperable data, advances in AI and analytics, open and secure platforms, and patient-centric care, which have the potential to deliver less costly and more productive drug development. If biopharma succeeds in capitalizing on AI’s potential, the internal and external productivity challenges driving the decline in the IRR of biopharma innovation could be reversed and enable the industry to thrive.

Seize the digital momentum

Unleash AI’s Potential

Read the full report to find out more about the current state of R&D returns in the biopharma industry



Read more about how our R&D ROI report is crafted by reading our methodology

Listen to our Life Sciences Connect podcast

Listen now

Access previous versions of the report:

2022: Seize the digital momentum
Download the report
2021: Nurturing growth
Download the report
2020: Seeds of change
Download the report
2019: Ten years on
Download the report
2018: Unlocking R&D productivity
Download the report
2017: A new future for R&D
Download the report
2016: Balancing the R&D equation
Download the report
2015: Transforming R&D returns
Download the report

Sign up for an in-depth analysis

Since 2010, Deloitte has been tracking the returns on R&D investment of the largest biopharma companies. Let us know if you have any questions or would be interested in receiving a more detailed analysis of your company's 2022 performance (available for select cohort companies).

  Yes         No

Key contacts

Kevin Dondarski

Principal, Deloitte Consulting LLP

Custom CSS

Insert Custom HTML fragment. Do not delete! This box/component contains code that is needed on this page. This message will not be visible when page is activated.